Notify Therapeutics has been selected to join the Presenting Company Class of 2022 at Bio€quity Europe.

Notify Therapeutics focuses on the initial ovarian follicle development to help infertile women, not benefitting from today’s standard hormone treatment. We are developing a first-in-class drug that regulates the intracellular AKT pathway; a major driver of follicle activation and a signal transduction pathway that promotes survival and growth in response to extracellular signals. This discovery can potentially provide hope for millions of women around the world for conceiving a genetically related child.

We will be participating in BioEquity with the purpose of raising additional funding for IND-enabling studies as well as phase 1b.